Area of research
Oncology · Molecular Biology
Research interest
Contact Email 415.514.1746 EYQUEM LAB WEBSITE Twitter LinkedIn Profile Justin Eyquem, PhD, is an affiliate investigator at Gladstone Institutes. He is also an assistant professor of medicine in the Division of Hematology and Oncology at UC San Francisco (UCSF). Eyquem seeks to optimize genetically modified immune T cells known as CAR-T cells to fight cancers and other diseases. To this end, he has been improving methods to edit the genome of human CAR-T cells and reprogram their functions. He is also developing animal models to assess their therapeutic efficacy in preclinical trials, and participating in multiple collaborations to facilitate their manufacturing for clinical use. He holds a Master’s degrees in bioengineering and genetics from the Paris School of Agronomy (AgroParisTech) and the University Paris VII, respectively. He earned his PhD in immunology and molecular biology from University Paris VII, and trained as a postdoctoral fellow in the laboratory of Michel Sadelain, MD, PhD, at Memorial Sloan-Kettering Cancer Center. He joined UCSF as a Parker Fellow in 2019, and the Gladstone-UCSF Institute of Genomic Immunology in 2022. Eyquem is a member of the Parker Institute for Cancer Immunotherapy, Bakar ImmunoX, and the UCSF Helen Diller Family Comprehensive Cancer Center. He is also co-founder and scientific advisor for Mnemo Therapeutics.
In vivo site-specific engineering to reprogram T cells
In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313
Integrated epigenetic and genetic programming of primary human T cells
Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells
SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy
Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells
T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes
Base-editing mutagenesis maps alleles to tune human T cell functions
An evolved AAV variant enables efficient genetic engineering of murine T cells
Modular pooled discovery of synthetic knockin sequences to program durable cell therapies
Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
RASA2 ablation in T cells boosts antigen sensitivity and long-term function
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
HLA-independent T cell receptors for targeting tumors with low antigen density
The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia
Modular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
A platform for rapid prototyping of synthetic gene networks in mammalian cells
1650 Owens Street, San Francisco, CA 94158 Crisis Response and Building Safety 415.734.2000
— 2000cited by 0position: selected